The artificial α1β1-contact mutant hemoglobin, Hb Phe-35β, shows only small functional abnormalities  by Nakatsukasa, Takashi et al.
The arti¢cial K1L1-contact mutant hemoglobin, Hb Phe-35L, shows only
small functional abnormalities
Takashi Nakatsukasaa;*, Noriko Nomuraa, Gentaro Miyazakia, Kiyohiro Imaib,
Yoshinao Wadac, Koichiro Ishimorid, Isao Morishimad, Hideki Morimotoa
aDivision of Biophysical Engineering, Graduate School of Engineering Science, Osaka University, Osaka 560-8531, Japan
bDivision of Physiology and Biosignaling, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
cOsaka Medical Center and Research Institute for Maternal and Child Health, Osaka 594-1101, Japan
dDivision of Molecular Engineering, Graduate School of Engineering, Kyoto University, Kyoto 606-8501, Japan
Received 1 October 1998; received in revised form 11 November 1998
Abstract It was previously reported that Hb Philly with a
mutation of Phe for Tyr at 35(C1)L showed non-cooperative
oxygen binding with a very high affinity and instability leading to
hemolysis. Further, it lacked the 1H-NMR signal at 13.1 ppm
from 2,2-dimethyl-2-silapentane-5-sulfonate in normal hemoglo-
bin (Hb A), so that this signal was assigned to a hydrogen bond
formed by Tyr-35(C1)L. Surprisingly, our artificial mutant
hemoglobin with the same mutation as Hb Philly showed slightly
lowered oxygen affinity, almost normal cooperativity, the 1H-
NMR signal at 13.1 ppm and no sign of instability. Our results
indicate that the mutation reported for Hb Philly and the
assignment of the 13.1 ppm signal need reexamination.
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1. Introduction
The atomic-level structure of the intersubunit contacts in
hemoglobin was extensively examined by X-ray crystallogra-
phy. The functional importance of the K1L2 interface has been
well documented [1,2]. This K1L2 interface undergoes an ex-
tensive relative movement and rearrangement of contact ami-
no acid residues upon ligand binding [3,4]. On the other hand,
the subunit interactions across the K1L1 interface have been
assigned minor importance compared to those across the
K1L2 interface. The K1L1 interface is so rigid as to be used
as the reference frame when the structures of deoxy and li-
ganded forms are compared [5].
The di¡erent contributions of these two types of subunit
interface to the structure and function of hemoglobin have
been well manifested in abnormal hemoglobins [6^9]. Gener-
ally, hemoglobin variants with amino acid substitutions at the
K1L2 interface showed markedly altered oxygen binding prop-
erties but normal stability. On the other hand, variants with
amino acid substitutions at the K1L1 interface usually showed
normal or only mildly altered oxygen binding properties
whereas stability was reduced, causing various degrees of he-
molysis in many cases [9,10]. The rate of the amino acid sub-
stitution at the K1L1 interface among vertebrate hemoglobins
is higher than that at the K1L2 interface [11]. These facts are
consistent with the idea that the K1L1 interface is rigid enough
to accommodate mutations without extensive changes of the
structure whereas mutations at the K1L2 interface often result
in crucial functional defects. However, it does not necessarily
mean that there is no functionally important interaction
across the K1L1 interface in hemoglobin.
Rieder et al. [12] reported that Hb Philly had a mutation at
the K1L1 contact where Tyr-35L was replaced by Phe, and, as
a result, the intersubunit hydrogen bond between Asp-126K
and Tyr-35L at the K1L1 contact in normal human hemoglo-
bin (Hb A) was removed in that mutant. It binds oxygen non-
cooperatively with very high a⁄nity and shows instability
leading to hemolysis. It shows nearly twice as many titratable
SH groups as Hb A. It lacks the exchangeable proton nuclear
magnetic resonance (NMR) signal at 13.1 ppm from 2,2-di-
methyl-2-silapentane-5-sulfonate (DSS) and this has been the
basis for the assignment of this signal to the hydrogen bond
described above [13]. The drastic change in oxygen binding
properties of Hb Philly has been only the exception to the rule
on the functional role of the K1L1 interface.
We therefore intended to investigate this apparent inconsis-
tency of the functional properties of Hb Philly, as well as the
exact role of Tyr-35L in Hb A. Since natural Hb Philly is not
available to us, we prepared an arti¢cial mutant Hb Phe-35L,
in which Tyr-35L was replaced by Phe, by site-directed muta-
genesis. We studied its oxygen binding properties, proton
NMR and the number of reactive SH groups.
2. Materials and methods
2.1. Preparation of mutant and normal hemoglobins
The mutant L-globin, in which Tyr-35L was replaced by Phe, was
prepared as described by Jessen et al. [15]. The mutated DNA se-
quence of the whole L chain was con¢rmed twice on the mutation
introduction vector M13 mp18 cIIFXL-globin and the expression vec-
tor pT7cIIFXL-globin using a DNA sequencer (model 373S, Applied
Biosystems). Since the properties of Hb Phe-35L were quite inconsis-
tent with those of the natural mutant, Hb Philly [12], and this was the
key to our study, we further checked the amino acid sequence of the
synthesized mutant L globin by means of fast-atom bombardment
mass spectrometry on tryptic digests [16]. The spectrum showed dis-
appearance of the peak with the mass to charge ratio of 1274.7 ac-
companied by appearance of a new peak with the ratio of 1258.8. No
other mass spectrum changes were noted for other peptide peaks. The
disappeared peak corresponded to the tryptic peptide from Leu-31L to
Arg-40L which includes Tyr-35L. The di¡erence of 15.9 agreed with
what is expected for the replacement of Tyr by Phe. Although the
replacement of Leu at 31L or 32L by Pro could be another possibility
giving nearly the same di¡erence by a single nucleotide replacement,
the DNA sequence data excluded this possibility.
This mutant L-globin was reconstituted into hemoglobin tetramer
as described by Jessen et al. [15]. The Hb A which was used as the
control in our experiments was puri¢ed from human adult red blood
cells [14].
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2.2. Titration of SH groups
The free SH groups for Hb A and Hb Phe-35L were titrated with
p-hydroxy-mercuribenzoate (PMB). Absorbance changes during titra-
tion were monitored at 250 nm [17].
2.3. Oxygen equilibrium experiments and analysis
Oxygen equilibrium curves were measured by using the method
developed by Imai et al. [18,19]. The light absorbance at 560 nm
was used to determine oxygen saturation of hemoglobin. The exper-
imental conditions were: 60 WM protein concentration on a heme
basis; in 50 mM Tris bu¡er (pH 8.4 and pH 7.9) or 50 mM Bis-
Tris bu¡er (pH 7.4 and pH 6.9) containing 0.1 M Cl3 ; at 25‡C.
The pH value was adjusted with a concentrated NaOH solution at
the same temperature as that for oxygen equilibrium measurements
(at 25‡C). To minimize the autoxidation of hemoglobin during the
measurement, catalase and superoxide dismutase were added to
each sample (approximately 0.1 WM as the ¢nal concentrations for
both of them)[20,21]. The methemoglobin content of the hemoglobin
samples as measured before and immediately after oxygen equilibrium
measurements ranged from 1.5% to 6.5% and 6.0% to 8.5%, respec-
tively. Although both the deoxygenation and reoxygenation curves
were recorded for each sample, the former one was adopted for the
analysis since the methemoglobin content was lower for the former.
They are comparatively low and do not in£uence the conclusions of
this paper.
P50 (partial pressure of oxygen at half saturation), the Hill coe⁄-
cient nmax (the maximum slope of the Hill plot) and K1 and K4 (the
intrinsic association equilibrium constants for the ¢rst and fourth
oxygen binding steps, respectively, the ¢rst and fourth Adair con-
stants) were evaluated from the oxygen equilibrium data by a least-
squares curve-¢tting method [22].
2.4. Proton NMR spectra
The 1H-NMR spectra of Hb Phe-35L and Hb A were recorded at
500 MHz using Bruker Avance DRX 500 as previously described [23].
Chemical shifts were referenced with respect to the proton resonance
of DSS. In this experiment, the proton resonance of H2O was 4.89
ppm (at 17‡C). The concentrations of Hb Phe-35L and Hb A were 2.0
mM and 2.9 mM on a heme basis, respectively.
3. Results and discussions
3.1. SH titration
The numbers of free SH groups obtained from titration
with PMB for both carbonmonoxy form Hb Phe-35L and
Hb A were 2.0 per tetramer. This result is in striking contrast
to Hb Philly which showed twice as many free SH groups as
Hb A.
3.2. Oxygen equilibrium curves
Oxygen equilibrium curves of Hb Phe-35L and Hb A were
determined at four di¡erent pH values: 6.9, 7.4, 7.9 and 8.4
without inositol hexaphosphate (IHP) and at pH 7.4 with
2 mM IHP. They are presented in Fig. 1 by means of the
Hill plot. Values of nmax, P50, K1 and K4 obtained from these
curves are listed in Table 1. The oxygen a⁄nity measured
by P50 for Hb Phe-35L was consistently lower (by 1.2^1.7-
fold) than that for Hb A under all the experimental condition
sets examined. However, the bottom asymptote of the Hill
plot for Hb Phe-35L was shifted toward the left compared
to that of Hb A under all the condition sets, suggesting that
there were some contaminant hemoglobin components with
high oxygen a⁄nity. Those contaminants, which could be
formed during protein expression in Escherichia coli, were
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Fig. 1. Hill plots of oxygen binding to Hb Phe-35L. Y, fractional
saturation of hemoglobin with oxygen; PO2, partial pressure of oxy-
gen (mm Hg). Symbols express observed points, and lines were cal-
culated from the best-¢t Adair constant values. E, pH 6.9; a, pH
7.4; O, pH 7.9; 7, pH 8.4; b, pH 7.4+2 mM IHP. Hemoglobin
concentration, 60 WM on a heme basis; in 50 mM Tris (pH 8.4 and
7.9) or 50 mM Bis-Tris (pH 7.4 and 6.9) containing 0.1 M Cl3, in
the presence of 0.1 WM catalase and 0.1 WM superoxide dismutase;
25‡C. Hill plots for Hb A in the same experimental conditions are
presented by thin lines without symbols. They are shown in the or-
der of decreasing pH from the left to the right and the rightmost is
pH 7.4+2 mM IHP.
Table 1
Oxygen equilibrium parameters for normal hemoglobin and hemo-
globin Phe-35La
P50b nmaxc K1d K4e NHf
Hb Phe35-L
pH 6.9 11.0 2.60 0.044 2.3
pH 7.4 6.1 2.80 0.076 3.9 30.41
pH 7.9 4.3 2.68 0.085 4.4
pH 8.4 3.5 2.67 0.10 4.6
pH 7.4+2 mM IHP 62.4 1.85 0.010 0.15
Hb A (normal Hb)
pH 6.9 7.6 3.01 0.020 4.6
pH 7.4 4.4 3.13 0.027 4.7 30.46
pH 7.9 2.6 2.89 0.070 5.2
pH 8.4 2.3 2.98 0.072 5.7
pH 7.4+2 mM IHP 51.9 2.42 0.0064 0.85
aExperimental conditions: Hb concentration, 60 WM on a heme basis;
in 50 mM Bis-Tris (pH 6.9 and 7.4) or Tris (pH 7.9 and 8.4) contain-
ing 0.1 M Cl3 ; 25‡C.
bPartial pressure of oxygen at half saturation (in mm Hg).
cMaximum slope of the Hill plot (Hill coe⁄cient).
dThe ¢rst stepwise Adair constant (in mm Hg31).
eThe fourth stepwise Adair constant (in mm Hg31).
fBohr coe⁄cient (=vlog P50/vpH).
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not thoroughly removed through subsequent puri¢cation pro-
cedures. Without these contaminants the mutant hemoglobin
would show still lower oxygen a⁄nity than the observed one.
The nmax values for Hb Phe-35L were somewhat smaller than
those for Hb A, probably due to the presence of the contam-
inants in Hb Phe-35L samples. The Bohr coe⁄cient for Hb
Phe-35L was 30.41 which was similar to that for Hb A
(30.46) (see Table 1). The oxygen equilibrium curves of Hb
Phe-35L measured at pHs 7.4, 7.9 and 8.4 asymptotically ap-
proach to those of Hb A measured in the same pH range. In
fact, K4 values for Hb Phe-35L are not very di¡erent from
those for Hb A at these pH values. On the other hand, at pH
6.9 the di¡erence becomes larger, being nearly double (Table
1). In the presence of 2 mM IHP the di¡erence is the largest
among the ¢ve condition sets. Although K1 values are most
in£uenced by the high a⁄nity contaminants other parameter
values in Table 1 are less in£uenced because they were deter-
mined from the middle and upper portions of the oxygen
equilibrium curve.
3.3. Proton NMR spectra
Fig. 2 shows the 1H-NMR spectra in the exchangeable pro-
ton resonance region for Hb Phe-35L and Hb A. The signals
at 14.2 ppm (a) and 11.2 ppm (d) (see Fig. 2A), which are
present only in the spectra for the deoxy form, have been
assigned to the hydrogen bonds between Tyr-42K and Asp-
99L and between Asp-94K and Trp-37L, respectively, at the
K1L2 interface [24^27]. These signals disappear in the oxy and
carbonmonoxy forms because these hydrogen bonds are bro-
ken due to the conformational change at the K1L2 interface
upon ligand binding. Thus, they have been used as spectro-
scopic probes for the deoxy quaternary structure [24,27]. The
characteristic peaks around 13.1 ppm and 12.2 ppm are com-
mon to all the three forms of Hb A. A 0.2 ppm downward
shift for the 12.2 ppm peak from the deoxy form (12.4 ppm)
to the liganded form (12.2 ppm) is noted in accordance with
Ho et al. [25,27]. These 13.1 ppm and 12.2 ppm peaks have
been assigned to the intersubunit hydrogen bonds between
Asp-126K and Tyr-35L and between His-103K and Asn-
108L, respectively, at the K1L1 interface [13,25]. These assign-
ments were based on the absence of the 13.1 ppm signal in Hb
Philly and the nuclear Overhauser e¡ect measurement. Russu
et al. [25] concluded from a structural consideration that the
nuclear Overhauser e¡ect for the 13.1 ppm signal was consis-
tent with the above assignment, and that the 12.2 ppm signal
must have originated from the other hydrogen bond. Since
isolated K and L chains showed none of these exchangeable
proton signals and those signals of Hb A did not change
signi¢cantly upon ligand binding, it appeared reasonable to
conclude that they originated from the K1L1 interface. In the
case of Hb Phe-35L both signals also show small downward
shifts, of 0.2 ppm (from 13.1 ppm to 12.9 ppm) for the 13.1
ppm peak and of 0.1 ppm (from 12.3 ppm to 12.2 ppm)
for the 12.2 ppm peak. If the assignment for the 13.1 ppm
signal described above was correct, that peak must be absent
in Hb Phe-35L. Thus, our recent results indicate that the pre-
vious assignment for the 13.1 ppm signal should be reex-
amined.
M. Nagai (personal communication) has shown that Hb
Phe-35L provided by us gave ultraviolet resonance Raman
spectra identical to those of Hb A, showing that the environ-
ments around Tyr-35L do not undergo large changes upon
ligand binding.
In conclusion, our present oxygen equilibrium data for Hb
Phe-35L accord with the rule that the amino acid substitutions
at K1L1 interface exert little in£uence on oxygen equilibrium
properties [28]. The most marked exception to this rule has
been removed by our present study. The apparent inconsis-
tency of the oxygen equilibrium data for Hb Philly, the pres-
ence of the 13.1 ppm 1H-NMR peak in Hb Phe-35L and the
disagreement of the number of free SH groups between Hb
Phe-35L and Hb Philly strongly indicate that Hb Phe-35L is
distinctly di¡erent from Hb Philly and, therefore, the amino
acid substitution in Hb Philly [12] and the assignment of the
13.1 ppm 1H-NMR peak [13] must be reexamined.
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Fig. 2. Proton NMR spectra (500 MHz) for the deoxy form (A),
the oxy form (B) and the CO form (C). The upper and lower spec-
tra stand for Hb Phe-35L and Hb A, respectively. Chemical shift is
given in ppm from DSS. Experimental conditions: protein concen-
tration, 2.94 mM (Hb A) and 2.01 mM (Hb Phe-35L) on a heme
basis; in 50 mM Bis-Tris (pH 7.4) containing 0.1 M Cl3 ; 17‡C.
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